Neointimal lesions
Education on Neointimal lesions and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Neointimal lesions and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Neointimal lesions?
Neointimal lesions is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Cardiovascular conditions affect the heart and blood vessels. The patent discusses oxidative stress, neutrophils, and AAT in vascular disease.
What Mark Egly's patent discusses
Neointimal lesions are vascular abnormalities that cause narrowing and even obliteration of the vessel lumen and contribute to the progressive increase in pulmonary vascular resistance that can lead to ventricular failure. As shown by Kim et al, lesions are associated with heightened lung neutrophil elastase ("NE") activity and PA elastin degradation. As a powerful inhibitor of NE, in one embodiment AAT may be used to treat, control, or prevent neointimal lesions in patients, either with or without known AATD. A diagnosis of neointimal lesions may prompt a medical provider to test a patient for AATD and to discover patients ongoing circulating ATT levels. Alternatively, a patient diagnosed with neointimal lesions may seek genetic testing for AATD through an independent genetic testing company such as 23andMe or geneology.com, a pharmaceutical company supplied test kit or other private methods available. A method for treating a patient suffering from neointimal lesions with AAT begins with the step of determining if the patient is AAT deficient or has lower AAT levels without being AATD. Determining if the patient is AAT deficient or has lower AAT levels without being AATD proceeds…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Neointimal lesions, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Neointimal lesions, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: